Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2
Sienna Biopharmaceuticals Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis
Eastern Metals Recommences ASX Trading – Aiming to Unlock High-Potential Copper Discoveries in New Brunswick, Canada